These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15252266)

  • 1. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease.
    Jiang C; Wan X; Jankovic J; Christian ST; Pristupa ZB; Niznik HB; Sundsmo JS; Le W
    Clin Neuropharmacol; 2004; 27(2):63-73. PubMed ID: 15252266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
    Yoshimura N; Kuno S; Chancellor MB; De Groat WC; Seki S
    Br J Pharmacol; 2003 Aug; 139(8):1425-32. PubMed ID: 12922929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats.
    Pahuja R; Seth K; Shukla A; Shukla RK; Bhatnagar P; Chauhan LK; Saxena PN; Arun J; Chaudhari BP; Patel DK; Singh SP; Shukla R; Khanna VK; Kumar P; Chaturvedi RK; Gupta KC
    ACS Nano; 2015 May; 9(5):4850-71. PubMed ID: 25825926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
    Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
    J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
    Stenslik MJ; Potts LF; Sonne JW; Cass WA; Turchan-Cholewo J; Pomerleau F; Huettl P; Ai Y; Gash DM; Gerhardt GA; Bradley LH
    J Neurosci Methods; 2015 Aug; 251():120-9. PubMed ID: 25999268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
    Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
    Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
    Waldmeier PC; Spooren WP; Hengerer B
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
    Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.